AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03938896 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: corticosteroid
Description: Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
Study NCT00414141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL
Description: 4 subcutaneous injections
Study NCT00414141 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 subcutaneous injections
Study NCT04100382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser and SLA
Description: Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
Study NCT04016909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aerobic exercise plus calorie restriction
Description: both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
Study NCT04491474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
Study NCT01080807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
Study NCT01080807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
Study NCT02420093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvis Support Assembly
Description: Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2.
Study NCT04268108 — intervention group
Intervention type: BIOLOGICAL
Intervention: liquid tumor infiltrating lymphocytes
Description: Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.
Study NCT02802566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BMI-based prenatal vitamin
Description: The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
Study NCT02802566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard prenatal vitamin
Description: Standard prenatal vitamin
Study NCT01550757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embedded Peer Mentor
Description: This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
Study NCT03560336 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
Study NCT04491474 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
Study NCT01939834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight CLC
Description: Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
Study NCT01939834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-Augmented Pump Therapy (SAP)
Description: The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.
Study NCT01300741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens (AIR OPTIX® AQUA)
Description: Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
Study NCT01300741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)
Description: Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
Study NCT01300741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens solution (Clear Care®)
Description: Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
Study NCT01300741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens solution (Clear Care®)
Description: Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
Study NCT04275375 — intervention group
Intervention type: OTHER
Intervention: observation study about the autonomic response after spinal anesthesia
Description: ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
Study NCT01822457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nike FuelBand (NFB)
Description: The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
Study NCT01809522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior reconstruction of the rhabdosphincter
Study NCT01361646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LC350189
Description: Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
Study NCT01361646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189
Description: Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
Study NCT01361646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LC350189
Description: Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
Study NCT01504022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecare, selfmonitoring, lifestyl behaviour
Description: Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
Study NCT03321084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MatPliates
Description: The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
Study NCT03321084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
Study NCT00295191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high-flux membrane
Description: high-flux dialyser
Study NCT00295191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low-flux membrane
Description: low-flux dialyser
Study NCT00295191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional dialysate
Description: conventional dialysate
Study NCT00295191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrapure dialysate
Description: ultrapure dialysate
Study NCT03101254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
Study NCT03101254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
Study NCT03101254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
Study NCT03170661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
Study NCT04353245 — intervention group
Intervention type: OTHER
Intervention: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM
Description: Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.
Study NCT02236468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced-Homestead Food Production Program (old)
Description: Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
Study NCT02236468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced-Homestead Food Production Program (old)
Description: Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
Study NCT02236468 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WASH/malaria behavior change
Description: WASH/malaria behavior change communication
Study NCT02236468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WASH/malaria behavior change
Description: WASH/malaria behavior change communication
Study NCT02236468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: LNS distribution
Description: Distribution of Nutributter (Fanga Degue) for children
Study NCT02236468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced-Homestead Food Production Program (new)
Description: Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
Study NCT02236468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced-Homestead Food Production Program (new)
Description: Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
Study NCT01914263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine induced killer cell
Description: The eligible patients are infused with a single dose of 8x10\^9 cord blood-derived cytokine indued killer cells.
Study NCT03958058 — intervention group
Intervention type: DRUG
Intervention: Anti-borrelial antibiotic therapy
Description: Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study NCT03958058 — intervention group
Intervention type: OTHER
Intervention: No antibiotic.
Description: Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study NCT00748345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin (drug)
Description: pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
Study NCT00900666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
Study NCT00900666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A (BTX-A)
Description: 200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
Study NCT04320017 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care
Description: * 12 derivations electrocardiogram done at baseline and repeated every 3 days~* transthoracic echocardiography at baseline~* clinical features at baseline: WHO performans status comorbidities and treatments~* biological results in routine care, such as baseline full blood count, inflammation markers: C-reactive protein, procalcitonin, interleukin-6 and ferritin, coagulation and troponin and brain natriuretic peptide
Study NCT04038489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg aspirin daily during AC-T chemotherapy
Study NCT04038489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Pill
Description: Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
Study NCT01743495 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 10 home-based functional services sessions over 4 months.
Description: The program consists of up to 10 home-based functional services sessions over 4 months.
Study NCT03430778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High end-tidal CO2
Description: maintaining of end-tidal CO2 with the range of 40-45 mmHg
Study NCT03430778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low CO2 group
Description: maintaining of end-tidal CO2 with the range of 30-35 mmHg
Study NCT00462007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stalevo
Description: Oral 3-4 daily doses for 6 weeks
Study NCT02444949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar
Study NCT02444949 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: intensity modulated radiation
Study NCT02444949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation
Study NCT02444949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Study NCT02444949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT03368365 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ventilotel ®
Description: Using of the spirometer of Aqsitania company, Ventilotel ®, to analyse the respiratory function at rest and to predict unplanned hospitalizations.
Study NCT02544607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.5mg/kg over 40 minutes IV
Study NCT06018948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.6
Description: Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour.
Study NCT06018948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.3
Description: Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour.
Study NCT06018948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion.
Study NCT02544607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI technology will be used before and after ketamine for patients with depression
Study NCT02912507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera enlighten laser
Description: high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
Study NCT04163029 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative oral care
Description: tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
Study NCT01966523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
Study NCT01966523 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study NCT00407186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin+capecitabine
Description: cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
Study NCT00407186 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 45 Gy in 25 fracions (5 days/week)
Study NCT00407186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin+cisplatin+capecitabine
Description: 3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
Study NCT02246959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process Incentive
Description: Daily sweepstake conditional on daily medication adherence
Study NCT02246959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outcome Incentive
Description: Incentives conditional on LDL cholesterol reduction